Version 1
: Received: 9 November 2023 / Approved: 10 November 2023 / Online: 13 November 2023 (08:32:29 CET)
How to cite:
Sadłecki, P.; Walentowicz-Sadłecka, M. Molecular Landscape of Borderline Ovarian Tumors: A Systematic Review. Preprints2023, 2023110716. https://doi.org/10.20944/preprints202311.0716.v1
Sadłecki, P.; Walentowicz-Sadłecka, M. Molecular Landscape of Borderline Ovarian Tumors: A Systematic Review. Preprints 2023, 2023110716. https://doi.org/10.20944/preprints202311.0716.v1
Sadłecki, P.; Walentowicz-Sadłecka, M. Molecular Landscape of Borderline Ovarian Tumors: A Systematic Review. Preprints2023, 2023110716. https://doi.org/10.20944/preprints202311.0716.v1
APA Style
Sadłecki, P., & Walentowicz-Sadłecka, M. (2023). Molecular Landscape of Borderline Ovarian Tumors: A Systematic Review. Preprints. https://doi.org/10.20944/preprints202311.0716.v1
Chicago/Turabian Style
Sadłecki, P. and Małgorzata Walentowicz-Sadłecka. 2023 "Molecular Landscape of Borderline Ovarian Tumors: A Systematic Review" Preprints. https://doi.org/10.20944/preprints202311.0716.v1
Abstract
Borderline ovarian tumors (BOTs) show intriguing characteristics distinguishing them from other ovarian tumors. This unique type of non-invasive neoplasms is characterized by atypical growth of epithelial cells, nuclear atypia, and a moderate-level mitotic activity that places BOTs between benign tumors and invasive cancers. Similar to invasive carcinomas, BOTs can be categorized into six histological subtypes based on the type of epithelial cells present. The most prevalent subtypes are serous and mucinous BOTs, whereas endometrioid, clear cell, seromucinous, and borderline Brenner tumors are diagnosed less often. Noticeably, molecular changes found in BOTs can vary on a case-by-case basis, which warrants further research on the molecular landscape of these tumors. Identifying carcinogenic mutations through molecular analysis and developing targeted therapies represent significant advancements in the diagnosis and treatment of ovarian malignancies.
A growing body of evidence indicates that BOTs often remain clinically dormant for extended periods before a molecular trigger initiates increased cell replication, potentially leading to carcinoma development or recurrence. Continued research in this area is crucial for improving risk assessment and developing personalized treatment approaches. While molecular studies have contributed significantly to our understanding of BOT pathogenesis, substantial research is still required to elucidate the relationship between ovarian neoplasms and extraneous disease, identify accurate prognostic indicators, and develop targeted therapeutic approaches. The aim of the present systematic review was to analyze the spectrum of molecular changes found in BOTs and discuss their significance in the context of the overall therapeutic approach.
Medicine and Pharmacology, Obstetrics and Gynaecology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
